This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Coronado Biosciences Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2012

BURLINGTON, Mass., March 14, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today its financial results for the fourth quarter and year ended December 31, 2012.

"We made significant strides in 2012 towards increasing the value of our product candidates and expanded our pipeline of clinical trials," said Dr. Harlan F. Weisman, Coronado's Chairman and CEO. "It was an important year for Coronado in that we signed a collaboration agreement with Dr. Falk Pharma GmbH (Falk) and Ovamed GmbH (Ovamed) for the development of TSO ( Trichuris suis ova or CNDO-201) for Crohn's disease, initiated TRUST-I, our phase 2 clinical trial of TSO in Crohn's disease, and initiated two investigator-initiated studies evaluating TSO in ulcerative colitis and autism spectrum disorders. Additionally, we commenced a phase 1/2 trial of CNDO-109 activated allogeneic natural killer (NK) cells, our second technology, in acute myeloid leukemia (AML). From a financial standpoint, in 2012, we conducted our first public offering with net proceeds of $26.5 million and secured a $15.0 million loan facility with Hercules Technology Growth Capital to further support our clinical development efforts.

"This is an exciting time for Coronado. We believe results from the two phase 2 trials in Crohn's disease, and possibly data from the autism study and the recently announced investigator-initiated psoriasis study, have the potential to positively validate the hygiene hypothesis and our mission to provide life-changing therapies for autoimmune diseases during 2013. We are committed to continuing our momentum throughout 2013, starting with the initiation of several more investigator-initiated studies for TSO in various autoimmune diseases in 2013."

Financial Highlights:
  • Coronado reported a net loss of $8.7 million, or $0.36 per share, for the fourth quarter of 2012 compared to a net loss of $6.7 million, or $0.52 per share, for the fourth quarter of 2011. For the year ended December 31, 2012, Coronado reported a net loss of $ 27.6 million, or $1.27 per share, compared to a net loss of $36.4 million, or $4.74 per share before the common stock dividend to Series A Preferred Stockholders, for 2011.
  • Research and development expenses were $17.5 million for the year ended December 31, 2012, compared to $8.6 million for 2011. General and administrative expenses totaled $8.7 million for the year ended December 31, 2012, compared to $5.8 million for 2011. In 2012, R&D included expenses related to the TSO clinical program and G&A included expenses related to the company's infrastructure growth and increased business activity.
  • At December 31, 2012, Coronado's cash and cash equivalents totaled $40.2 million. During the first quarter of 2013, and through March 13, 2013, the company sold an aggregate of approximately 1.4 million shares of common stock under an at market issuance facility for net proceeds of $10.5 million.

Recent Corporate and Scientific Highlights:
  • Initiated phase 1/2 trial of CNDO-109 activated allogeneic NK cells in AML
  • Signed Clinical Trial Agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to evaluate TSO for the treatment of ulcerative colitis in a multi-center phase 2 clinical trial that will be conducted by the NIAID-funded Autoimmunity Centers of Excellence (ACE)
  • Acquired manufacturing rights to TSO from Ovamed, for North America, South America, and Japan, Coronado's licensed territory and, in conjunction therewith, acquired a lease agreement to establish a manufacturing facility in Woburn, MA to produce TSO
  • Appointed Dr. Harlan F. Weisman, a director for the company since August 2012, Chairman and CEO
  • Signed Research Collaboration and License Agreement with Freie Universität Berlin for secretory products of Trichuris suis
  • Commenced an investigator-initiated study evaluating TSO in psoriasis

Upcoming Events:

Conference Call and Webcast Information

Coronado management will review its fourth quarter and year-end financial results and development programs via conference call and webcast today at 8:30 AM EDT. To participate in the conference call, please dial 877-312-5413 (toll free from the US and Canada), or 253-237-1511 (for international callers). Investors may also access a live audio webcast of the call at on the Events & Webcasts page.

A replay of the webcast will be available shortly after the conclusion of the call. The webcast archive will remain available for one year. An audio replay will also be available shortly after the conclusion of the call and will be made available until March 24, 2013. The audio replay can be accessed by dialing 855-859-2056 (toll free from the US and Canada), or 404-537-3406 (for international callers) and entering Event ID 15400780.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.30 -0.92%
FB $118.08 0.55%
GOOG $695.81 0.50%
TSLA $234.18 0.80%
YHOO $35.97 -0.11%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs